Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas.

PubWeight™: 8.79‹?› | Rank: Top 0.1%

🔗 View Article (PMID 7926468)

Published in Gastroenterology on October 01, 1994


C E Eberhart1, R J Coffey, A Radhika, F M Giardiello, S Ferrenbach, R N DuBois

Author Affiliations

1: Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.

Articles citing this

(truncated to the top 100)

Aspirin use and survival after diagnosis of colorectal cancer. JAMA (2009) 6.93

Eicosanoids and cancer. Nat Rev Cancer (2010) 5.96

PPARdelta is an APC-regulated target of nonsteroidal anti-inflammatory drugs. Cell (1999) 5.12

Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci U S A (1997) 4.84

Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci U S A (1999) 4.16

Long-term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of colorectal cancer. JAMA (2005) 3.88

Aspirin triggers previously undescribed bioactive eicosanoids by human endothelial cell-leukocyte interactions. Proc Natl Acad Sci U S A (1995) 3.72

Inflammation and cancer: interweaving microRNA, free radical, cytokine and p53 pathways. Carcinogenesis (2009) 3.40

Primary prevention of colorectal cancer. Gastroenterology (2010) 3.20

Reduced colon cancer incidence and mortality in postmenopausal women treated with an oral bisphosphonate--Danish National Register Based Cohort Study. Osteoporos Int (2012) 3.13

Effect of anti-inflammatory drugs on overall risk of common cancer: case-control study in general practice research database. BMJ (2000) 3.10

Altered expression of the mRNA stability factor HuR promotes cyclooxygenase-2 expression in colon cancer cells. J Clin Invest (2001) 3.01

Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2. J Clin Invest (1997) 2.99

Mechanisms underlying nonsteroidal antiinflammatory drug-mediated apoptosis. Proc Natl Acad Sci U S A (1998) 2.83

Aspirin dose and duration of use and risk of colorectal cancer in men. Gastroenterology (2007) 2.73

The role of COX-2 in intestinal inflammation and colorectal cancer. Oncogene (2009) 2.72

Differential expression of cyclooxygenase 2 in human colorectal cancer. Gut (1999) 2.62

The chromosomal instability pathway in colon cancer. Gastroenterology (2010) 2.59

Exacerbation of inflammation-associated colonic injury in rat through inhibition of cyclooxygenase-2. J Clin Invest (1996) 2.31

The AOM/DSS murine model for the study of colon carcinogenesis: From pathways to diagnosis and therapy studies. J Carcinog (2011) 2.30

CXCL1 induced by prostaglandin E2 promotes angiogenesis in colorectal cancer. J Exp Med (2006) 2.30

Prostacyclin-mediated activation of peroxisome proliferator-activated receptor delta in colorectal cancer. Proc Natl Acad Sci U S A (2000) 2.23

A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis. Gut (2002) 2.22

Selective inhibition of vascular endothelial growth factor-mediated angiogenesis by cyclosporin A: roles of the nuclear factor of activated T cells and cyclooxygenase 2. J Exp Med (2001) 2.22

Epidermal growth factor receptor activation induces nuclear targeting of cyclooxygenase-2, basolateral release of prostaglandins, and mitogenesis in polarizing colon cancer cells. Proc Natl Acad Sci U S A (1997) 2.12

Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial. Lancet Oncol (2012) 2.06

The mRNA binding proteins HuR and tristetraprolin regulate cyclooxygenase 2 expression during colon carcinogenesis. Gastroenterology (2009) 1.92

Prostaglandin H synthase 2 is expressed abnormally in human colon cancer: evidence for a transcriptional effect. Proc Natl Acad Sci U S A (1996) 1.88

Risk of cardiovascular events in a randomized placebo-controlled, double-blind trial of difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas. Cancer Prev Res (Phila) (2009) 1.86

Intracellular unesterified arachidonic acid signals apoptosis. Proc Natl Acad Sci U S A (2000) 1.85

Carcinogenesis in IBD: potential targets for the prevention of colorectal cancer. Nat Rev Gastroenterol Hepatol (2009) 1.80

Inflammation and cancer: how friendly is the relationship for cancer patients? Curr Opin Pharmacol (2009) 1.78

Lipid droplets: a new player in colorectal cancer stem cells unveiled by spectroscopic imaging. Stem Cells (2015) 1.75

Induction of cyclooxygenase-2 in a mouse model of Peutz-Jeghers polyposis. Proc Natl Acad Sci U S A (2002) 1.67

Selective visualization of cyclooxygenase-2 in inflammation and cancer by targeted fluorescent imaging agents. Cancer Res (2010) 1.66

Inflammation and cancer: advances and new agents. Nat Rev Clin Oncol (2015) 1.65

Alternative polyadenylation of cyclooxygenase-2. Nucleic Acids Res (2005) 1.61

COX-2 expression is associated with an aggressive phenotype in ductal carcinoma in situ. Br J Cancer (2004) 1.59

Identification of a human enterocyte lipoxin A4 receptor that is regulated by interleukin (IL)-13 and interferon gamma and inhibits tumor necrosis factor alpha-induced IL-8 release. J Exp Med (1998) 1.58

The absence of LPA2 attenuates tumor formation in an experimental model of colitis-associated cancer. Gastroenterology (2009) 1.56

Aspirin-triggered lipoxins (15-epi-LX) are generated by the human lung adenocarcinoma cell line (A549)-neutrophil interactions and are potent inhibitors of cell proliferation. Mol Med (1996) 1.55

A 22-year prospective study of fish, n-3 fatty acid intake, and colorectal cancer risk in men. Cancer Epidemiol Biomarkers Prev (2008) 1.53

Reversal of gene expression changes in the colorectal normal-adenoma pathway by NS398 selective COX2 inhibitor. Br J Cancer (2010) 1.51

Cyclooxygenase-2 expression in Helicobacter pylori-associated premalignant and malignant gastric lesions. Am J Pathol (2000) 1.50

Malignant transformation and antineoplastic actions of nonsteroidal antiinflammatory drugs (NSAIDs) on cyclooxygenase-null embryo fibroblasts. J Exp Med (1999) 1.48

The activating mutation R201C in GNAS promotes intestinal tumourigenesis in Apc(Min/+) mice through activation of Wnt and ERK1/2 MAPK pathways. Oncogene (2010) 1.45

Mouse embryonic stem cells carrying one or two defective Msh2 alleles respond abnormally to oxidative stress inflicted by low-level radiation. Proc Natl Acad Sci U S A (1998) 1.45

Cyclooxygenase-2 and cancer treatment: understanding the risk should be worth the reward. Clin Cancer Res (2010) 1.44

Mutagenicity in Escherichia coli of the major DNA adduct derived from the endogenous mutagen malondialdehyde. Proc Natl Acad Sci U S A (1997) 1.43

Localization of cyclooxygenase-2 in human sporadic colorectal adenomas. Am J Pathol (2000) 1.42

Non-steroidal anti-inflammatory drugs and the chemoprevention of colorectal and oesophageal cancers. Gut (1996) 1.42

Cancer-associated immunodeficiency and dendritic cell abnormalities mediated by the prostaglandin EP2 receptor. J Clin Invest (2003) 1.42

Tumor cells and tumor-associated macrophages: secreted proteins as potential targets for therapy. Clin Dev Immunol (2011) 1.41

Suppression of colitis-related mouse colon carcinogenesis by a COX-2 inhibitor and PPAR ligands. BMC Cancer (2005) 1.39

Translation regulatory factor RBM3 is a proto-oncogene that prevents mitotic catastrophe. Oncogene (2008) 1.37

Prostaglandin E2 receptor distribution and function in the gastrointestinal tract. Br J Pharmacol (2006) 1.36

Pro-inflammatory prostaglandins and progression of colorectal cancer. Cancer Lett (2008) 1.32

Regulation of inflammation in cancer by eicosanoids. Prostaglandins Other Lipid Mediat (2011) 1.31

Cyclooxygenase-2 overexpression correlates with tumour recurrence, especially haematogenous metastasis, of colorectal cancer. Br J Cancer (2000) 1.31

Inhibition of apoptosis in normal and transformed intestinal epithelial cells by cAMP through induction of inhibitor of apoptosis protein (IAP)-2. Proc Natl Acad Sci U S A (2003) 1.30

Down-regulation of cytokine-induced cyclo-oxygenase-2 transcript isoforms by dexamethasone: evidence for post-transcriptional regulation. Biochem J (1996) 1.30

Cyclooxygenase 2-implications on maintenance of gastric mucosal integrity and ulcer healing: controversial issues and perspectives. Gut (2001) 1.29

A cyclooxygenase-2 homologue encoded by rhesus cytomegalovirus is a determinant for endothelial cell tropism. J Virol (2004) 1.28

The role of cyclooxygenase 2 in ulcerative colitis-associated neoplasia. Am J Pathol (2000) 1.27

Caveolae structure and function. J Cell Mol Med (2008) 1.26

Curcumin modulates the radiosensitivity of colorectal cancer cells by suppressing constitutive and inducible NF-kappaB activity. Int J Radiat Oncol Biol Phys (2009) 1.26

The Role of PPARs in Cancer. PPAR Res (2008) 1.26

Inhibition of haematogenous metastasis of colon cancer in mice by a selective COX-2 inhibitor, JTE-522. Br J Cancer (1999) 1.25

Aspirin use and potential mechanisms for colorectal cancer prevention. J Clin Invest (1997) 1.25

Evidence for colorectal cancer cell specificity of aspirin effects on NF kappa B signalling and apoptosis. Br J Cancer (2004) 1.24

The tumor microenvironment in colorectal carcinogenesis. Cancer Microenviron (2010) 1.23

Regular use of analgesics is a risk factor for renal cell carcinoma. Br J Cancer (1999) 1.23

Cyclooxygenase 2 is up-regulated and localized to macrophages in the intestine of Min mice. Br J Cancer (1999) 1.22

Prostaglandin E2 EP receptors as therapeutic targets in breast cancer. Cancer Metastasis Rev (2011) 1.21

Cyclooxygenase-1 is up-regulated in cervical carcinomas: autocrine/paracrine regulation of cyclooxygenase-2, prostaglandin e receptors, and angiogenic factors by cyclooxygenase-1. Cancer Res (2002) 1.20

Frequent co-localization of Cox-2 and laminin-5 gamma2 chain at the invasive front of early-stage lung adenocarcinomas. Am J Pathol (2002) 1.19

Nonsteroidal anti-inflammatory drugs: effects on mortality after colorectal cancer diagnosis. Cancer (2009) 1.19

Cannabinoids and cancer: pros and cons of an antitumour strategy. Br J Pharmacol (2006) 1.18

Colonic crypt cell proliferation state assessed by whole crypt microdissection in sporadic neoplasia and familial adenomatous polyposis. Gut (2001) 1.16

The mRNA of L-type calcium channel elevated in colon cancer: protein distribution in normal and cancerous colon. Am J Pathol (2000) 1.15

Biological activity of celecoxib in the bronchial epithelium of current and former smokers. Cancer Prev Res (Phila) (2010) 1.15

Inhibition of 11beta-hydroxysteroid dehydrogenase type II selectively blocks the tumor COX-2 pathway and suppresses colon carcinogenesis in mice and humans. J Clin Invest (2009) 1.14

Peroxisome-proliferator-activated receptor alpha agonists inhibit cyclo-oxygenase 2 and vascular endothelial growth factor transcriptional activation in human colorectal carcinoma cells via inhibition of activator protein-1. Biochem J (2006) 1.14

Levels of rectal mucosal polyamines and prostaglandin E2 predict ability of DFMO and sulindac to prevent colorectal adenoma. Gastroenterology (2010) 1.14

The EP4 receptor antagonist, L-161,982, blocks prostaglandin E2-induced signal transduction and cell proliferation in HCA-7 colon cancer cells. Exp Cell Res (2007) 1.13

Synergistic effects of RXR alpha and PPAR gamma ligands to inhibit growth in human colon cancer cells--phosphorylated RXR alpha is a critical target for colon cancer management. Gut (2007) 1.12

Inflammation and cancer. World J Gastrointest Surg (2012) 1.12

A novel sulindac derivative that potently suppresses colon tumor cell growth by inhibiting cGMP phosphodiesterase and β-catenin transcriptional activity. Cancer Prev Res (Phila) (2012) 1.11

Prevention and management of duodenal polyps in familial adenomatous polyposis. Gut (2005) 1.09

Targeting the tumor microenvironment: focus on angiogenesis. J Oncol (2011) 1.09

Prostaglandins in cancer cell adhesion, migration, and invasion. Int J Cell Biol (2012) 1.09

Molecular targets of aspirin and cancer prevention. Br J Cancer (2014) 1.09

Changes of the mucosal n3 and n6 fatty acid status occur early in the colorectal adenoma-carcinoma sequence. Gut (1996) 1.08

Expression of COX-2, NF-kappaB-p65, NF-kappaB-p50 and IKKalpha in malignant and adjacent normal human colorectal tissue. Br J Cancer (2009) 1.08

Alterations in lipoxygenase and cyclooxygenase-2 catalytic activity and mRNA expression in prostate carcinoma. Neoplasia (2001) 1.08

Tissue prostanoids as biomarkers for chemoprevention of colorectal neoplasia: correlation between prostanoid synthesis and clinical response in familial adenomatous polyposis. Prostaglandins Other Lipid Mediat (2000) 1.08

Urinary prostaglandin E2 metabolite and risk for colorectal adenoma. Cancer Prev Res (Phila) (2011) 1.08

Selective cyclo-oxygenase-2 inhibitors aggravate ischaemia-reperfusion injury in the rat stomach. Br J Pharmacol (1999) 1.07

Cyclooxygenase-2 and its role in colorectal cancer development. Virchows Arch (2004) 1.07

Tumor-associated down-regulation of 15-lipoxygenase-1 is reversed by celecoxib in colorectal cancer. Ann Surg (2005) 1.07

Articles by these authors

Targeted disruption of the Stat1 gene in mice reveals unexpected physiologic specificity in the JAK-STAT signaling pathway. Cell (1996) 10.49

Colorectal cancer screening: clinical guidelines and rationale. Gastroenterology (1997) 9.70

The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med (2000) 7.54

Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell (1998) 7.25

Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell (1995) 6.69

The role of cyclooxygenases in inflammation, cancer, and development. Oncogene (1999) 5.50

Familial colorectal cancer in Ashkenazim due to a hypermutable tract in APC. Nat Genet (1997) 4.86

Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci U S A (1997) 4.84

Increased risk of cancer in the Peutz-Jeghers syndrome. N Engl J Med (1987) 4.55

Production and auto-induction of transforming growth factor-alpha in human keratinocytes. Nature (1987) 4.19

Molecular diagnosis of familial adenomatous polyposis. N Engl J Med (1993) 4.07

Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res (1998) 3.79

Trefoil peptides: less clandestine in the intestine. Science (1996) 3.60

The risk of upper gastrointestinal cancer in familial adenomatous polyposis. Gastroenterology (1992) 3.59

Prostaglandin E2 increases growth and motility of colorectal carcinoma cells. J Biol Chem (2001) 3.40

A multi-institutional experience with stereotactic radiosurgery for solitary brain metastasis. Int J Radiat Oncol Biol Phys (1994) 3.29

Targeting cyclooxygenase 2 and HER-2/neu pathways inhibits colorectal carcinoma growth. Gastroenterology (2001) 3.13

Host cyclooxygenase-2 modulates carcinoma growth. J Clin Invest (2000) 3.03

Lymphocytic ("microscopic") colitis: a comparative histopathologic study with particular reference to collagenous colitis. Hum Pathol (1989) 3.02

Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2. J Clin Invest (1997) 2.99

Synergistic interaction between hypergastrinemia and Helicobacter infection in a mouse model of gastric cancer. Gastroenterology (2000) 2.99

Collagenous colitis with mucosal tears on endoscopic insufflation: a unique presentation. Gut (2002) 2.81

Inhibition of apoptosis during development of colorectal cancer. Cancer Res (1995) 2.77

Hypoxia induces cyclooxygenase-2 via the NF-kappaB p65 transcription factor in human vascular endothelial cells. J Biol Chem (1997) 2.66

Overexpression of transforming growth factor alpha in psoriatic epidermis. Science (1989) 2.63

Development of mammary hyperplasia and neoplasia in MMTV-TGF alpha transgenic mice. Cell (1990) 2.63

Stereotactic radiosurgery for arteriovenous malformations of the brain. J Neurosurg (1991) 2.41

Cyclo-oxygenase-2-derived prostacyclin mediates embryo implantation in the mouse via PPARdelta. Genes Dev (1999) 2.37

Antioxidants enhance the cytotoxicity of chemotherapeutic agents in colorectal cancer: a p53-independent induction of p21WAF1/CIP1 via C/EBPbeta. Nat Med (1997) 2.32

Prostacyclin-mediated activation of peroxisome proliferator-activated receptor delta in colorectal cancer. Proc Natl Acad Sci U S A (2000) 2.23

Targeted disruption of the Kvlqt1 gene causes deafness and gastric hyperplasia in mice. J Clin Invest (2000) 2.17

A new type of transforming growth factor-beta, TGF-beta 3. EMBO J (1988) 2.12

Epidermal growth factor receptor activation induces nuclear targeting of cyclooxygenase-2, basolateral release of prostaglandins, and mitogenesis in polarizing colon cancer cells. Proc Natl Acad Sci U S A (1997) 2.12

The prevalence of MADH4 and BMPR1A mutations in juvenile polyposis and absence of BMPR2, BMPR1B, and ACVR1 mutations. J Med Genet (2004) 2.10

Regulation of intestinal epithelial cell growth by transforming growth factor type beta. Proc Natl Acad Sci U S A (1989) 2.09

Desmoid tumours in familial adenomatous polyposis. Gut (1994) 2.08

Mammary tumor suppression by transforming growth factor beta 1 transgene expression. Proc Natl Acad Sci U S A (1995) 2.07

Celecoxib prevents tumor growth in vivo without toxicity to normal gut: lack of correlation between in vitro and in vivo models. Cancer Res (2000) 2.05

Type beta transforming growth factor reversibly inhibits the early proliferative response to partial hepatectomy in the rat. Proc Natl Acad Sci U S A (1988) 2.03

Chronic colitis with thickening of the subepithelial collagen layer (collagenous colitis): histopathologic findings in 15 patients. Hum Pathol (1987) 1.97

Metalloprotease-mediated ligand release regulates autocrine signaling through the epidermal growth factor receptor. Proc Natl Acad Sci U S A (1999) 1.96

Expression and localization of the matrix metalloproteinase pump-1 (MMP-7) in human gastric and colon carcinomas. Mol Carcinog (1991) 1.95

Prostaglandin endoperoxide synthase: why two isoforms? Am J Physiol (1996) 1.91

Expansion of Pdx1-expressing pancreatic epithelium and islet neogenesis in transgenic mice overexpressing transforming growth factor alpha. Gastroenterology (1999) 1.88

Hepatic processing of transforming growth factor beta in the rat. Uptake, metabolism, and biliary excretion. J Clin Invest (1987) 1.88

Phenotypic and molecular characteristics of hyperplastic polyposis. Gastroenterology (2000) 1.86

The effects of sulindac on colorectal proliferation and apoptosis in familial adenomatous polyposis. Gastroenterology (1995) 1.86

Variable phenotype of familial adenomatous polyposis in pedigrees with 3' mutation in the APC gene. Gut (1998) 1.85

Increased cyclooxygenase-2 levels in carcinogen-induced rat colonic tumors. Gastroenterology (1996) 1.81

Cholangiocarcinoma complicating primary sclerosing cholangitis. Ann Surg (1991) 1.78

Transforming growth factor-beta1 enhances Ha-ras-induced expression of cyclooxygenase-2 in intestinal epithelial cells via stabilization of mRNA. J Biol Chem (2000) 1.77

Elevated content of the tyrosine kinase substrate phospholipase C-gamma 1 in primary human breast carcinomas. Proc Natl Acad Sci U S A (1991) 1.77

Complex regulation of transforming growth factor beta 1, beta 2, and beta 3 mRNA expression in mouse fibroblasts and keratinocytes by transforming growth factors beta 1 and beta 2. Mol Cell Biol (1989) 1.76

Prevalence and importance of pigmented ocular fundus lesions in Gardner's syndrome. N Engl J Med (1987) 1.76

Cyclooxygenase 2 expression is increased in the stroma of colon carcinomas from IL-10(-/-) mice. Gastroenterology (2000) 1.75

Epidermal growth factor-related peptides and their relevance to gastrointestinal pathophysiology. Gastroenterology (1995) 1.74

Production of transforming growth factors by human colon cancer lines. Cancer Res (1986) 1.74

Pathogenesis of adenocarcinoma in Peutz-Jeghers syndrome. Cancer Res (1998) 1.73

Decreased expression of the gut-enriched Krüppel-like factor gene in intestinal adenomas of multiple intestinal neoplasia mice and in colonic adenomas of familial adenomatous polyposis patients. FEBS Lett (2000) 1.70

Localization of transforming growth factor alpha and its receptor in gastric mucosal cells. Implications for a regulatory role in acid secretion and mucosal renewal. J Clin Invest (1989) 1.69

Suramin inhibition of growth factor receptor binding and mitogenicity in AKR-2B cells. J Cell Physiol (1987) 1.68

Transforming growth factors and control of neoplastic cell growth. J Cell Biochem (1987) 1.67

Elevated cyclooxygenase-2 levels in Min mouse adenomas. Gastroenterology (1996) 1.65

Stereotactic gamma knife radiosurgery. Initial North American experience in 207 patients. Arch Neurol (1990) 1.64

Colorectal cancer and nonsteroidal anti-inflammatory drugs. Adv Pharmacol (1997) 1.63

Sporadic fundic gland polyps: common gastric polyps arising through activating mutations in the beta-catenin gene. Am J Pathol (2001) 1.61

Transforming growth factor alpha and beta expression in human colon cancer lines: implications for an autocrine model. Cancer Res (1987) 1.61

Her-2/neu overexpression induces NF-kappaB via a PI3-kinase/Akt pathway involving calpain-mediated degradation of IkappaB-alpha that can be inhibited by the tumor suppressor PTEN. Oncogene (2001) 1.59

Rectal epithelial apoptosis in familial adenomatous polyposis patients treated with sulindac. Gut (1999) 1.59

Regulation of constitutive cyclooxygenase-2 expression in colon carcinoma cells. J Biol Chem (2000) 1.58

Gamma knife for glioma: selection factors and survival. Int J Radiat Oncol Biol Phys (1996) 1.56

Sulindac targets nuclear beta-catenin accumulation and Wnt signalling in adenomas of patients with familial adenomatous polyposis and in human colorectal cancer cell lines. Br J Cancer (2004) 1.54

Reversible drug-induced oxyntic atrophy in rats. Gastroenterology (2000) 1.53

Fatal progression of posttraumatic dural arteriovenous fistulas refractory to multimodal therapy. Case report. J Neurosurg (2001) 1.53

Identification of rCop-1, a new member of the CCN protein family, as a negative regulator for cell transformation. Mol Cell Biol (1998) 1.52

Target genes of peroxisome proliferator-activated receptor gamma in colorectal cancer cells. J Biol Chem (2001) 1.48

Activation of the Raf-1/MAP kinase cascade is not sufficient for Ras transformation of RIE-1 epithelial cells. Proc Natl Acad Sci U S A (1996) 1.46

Fundic gland polyps in familial adenomatous polyposis: neoplasms with frequent somatic adenomatous polyposis coli gene alterations. Am J Pathol (2000) 1.44

Global gene expression analysis to identify molecular markers of uterine receptivity and embryo implantation. J Biol Chem (2001) 1.43

Mucosal prolapse in the pathogenesis of Peutz-Jeghers polyposis. Gut (2006) 1.42

Crk-associated substrate p130(Cas) interacts with nephrocystin and both proteins localize to cell-cell contacts of polarized epithelial cells. Exp Cell Res (2000) 1.42

Large genomic deletions of SMAD4, BMPR1A and PTEN in juvenile polyposis. Gut (2008) 1.41

Auto- and cross-induction within the mammalian epidermal growth factor-related peptide family. J Biol Chem (1994) 1.40

Geographical variance in the risk of gastric stump cancer: no increased risk in Japan? Jpn J Cancer Res (1991) 1.39

A filing system for the gastroenterology/hepatology consultant. Am J Gastroenterol (1995) 1.39

Predictors of survival after curative resection of carcinoma of the colon and rectum. Cancer (1987) 1.37

Synergistic interaction of the Neu proto-oncogene product and transforming growth factor alpha in the mammary epithelium of transgenic mice. Mol Cell Biol (1996) 1.36

A selective cyclooxygenase 2 inhibitor suppresses the growth of H-ras-transformed rat intestinal epithelial cells. Gastroenterology (1997) 1.35

Hepatobiliary carcinoma associated with primary sclerosing cholangitis and chronic ulcerative colitis. Hum Pathol (1985) 1.34

Germline SMAD4 or BMPR1A mutations and phenotype of juvenile polyposis. Ann Surg Oncol (2002) 1.34

Induction of cancer cell apoptosis by alpha-tocopheryl succinate: molecular pathways and structural requirements. FASEB J (2001) 1.33

The role of nonsteroidal anti-inflammatory drugs in colorectal cancer prevention. Eur J Cancer (1995) 1.32

Amphiregulin messenger RNA is elevated in psoriatic epidermis and gastrointestinal carcinomas. Cancer Res (1992) 1.32

Collagenous colitis: physiologic and histopathologic studies in seven patients. Ann Intern Med (1987) 1.32

Cell surface ectodomain cleavage of human amphiregulin precursor is sensitive to a metalloprotease inhibitor. Release of a predominant N-glycosylated 43-kDa soluble form. J Biol Chem (1998) 1.30

Targeted disruption of the epidermal growth factor receptor impairs growth of squamous papillomas expressing the v-ras(Ha) oncogene but does not block in vitro keratinocyte responses to oncogenic ras. Cancer Res (1997) 1.27